Treats mild to moderate atopic dermatitis. ANDA 210209, held by Lupin. Hydrocortisone Butyrate.
As of Nov 16, 2026, ANDA 210209 (Hydrocortisone Butyrate), held by Lupin, was first approved by FDA on Aug 17, 2018, with 0 approved supplements and 0 published complete response letters.
Hydrocortisone butyrate lotion, 0.1% is indicated for the topical treatment of mild to moderate atopic dermatitis in patients 3 months of age and older.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 17, 2018 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Hydrocortisone Butyrate0.1% · lotion;topical | Hydrocortisone Butyrate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters